Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT07065435
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
74 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HER2 + Breast Cancer
ACTIVE_NOT_RECRUITING
NCT05650879
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
198 Enrollment(s)
39 Study location(s)
INTERVENTIONAL (PHASE1)
HER2 Mutant Non-small Cell Lung Cancer


HER2-positive Metastatic Breast Cancer


HER2 Gene Mutation


HER2 Amplification
ACTIVE_NOT_RECRUITING
NCT04010955
Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
1,200 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Acute Ischemic Stroke


Atrial Fibrillation


Extracranial Atherosclerosis


Intracranial Atherosclerosis


Coronary Artery Atherosclerosis


Peripheral Artery Stenosis


Anticoagulant


Antiplatelet
RECRUITING
NCT06846996
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
260 Enrollment(s)
36 Study location(s)
OBSERVATIONAL (None)
HER2-positive Gastric Cancer


HER2-positive Gastroesophageal Junction
COMPLETED
NCT06833268
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
228 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
HER2-positive Breast Cancer
COMPLETED
NCT03430661
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
77 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Healthy
RECRUITING
NCT06058988
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
30 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Brain Cancer


Glioblastoma


Metastatic Cancer


Leptomeningeal Metastasis


Recurrent Glioblastoma
RECRUITING
NCT06727227
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
135 Enrollment(s)
14 Study location(s)
OBSERVATIONAL (None)
Breast Cancer